Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Ludwig Insitute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia.

Survival: monthsCountry:Australia
Toxiciy Grade:3City/State/Province:Heidelberg, Victoria
Treatments:ImmunotherapyHospital:Ludwig Insitute for Cancer Research, Austin Hospital
Drugs:Journal:Link
Date:Mar 2009

Description:

Patients: This study involved 24 people with stage IV malignant melanoma. They had not previously received treatment for their cancer. There were 14 men and 10 women in this study. Their median age was 54.5, ranging from 25 to 67 years of age.

Treatment: Patients were treated with an immunotherapy, interleukin-21.

Toxicity: No grade 4 or 5 toxicities were reported. The most common grade 3 toxicity was leucopenia (low number of lymphocytes), which was reported in about 70% of patients. The most common grade 1 and 2 toxicities were abnormal laboratory tests (which returned to normal when the therapy was not being given), rash, pyrexia (fever), fatigue, headache, nausea, flu-like illness, leucopenia, and low platelets.

Results: The median overall survival was 9.2 months.

Correspondence: Dr. Ian Davis



Back